Clinical Trials
27 trialsNCT04588246 2026-05-20
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Phase 3 Terminated
NCT04739761 2026-05-12
DESTINY-B12
AstraZeneca
Phase 3 Active not recruiting
NCT06057168 2026-01-29
GDX-44-016
Guerbet
Phase 3 Completed
NCT04410133 2025-08-28
REVELATE
Blue Earth Diagnostics
Phase 3 Completed
NCT02667587 2025-06-18
CheckMate548
Bristol-Myers Squibb
Phase 3 Completed
NCT02360215 2025-04-23
Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
NRG Oncology
Phase 3 Completed
NCT03632135 2025-04-15
CSCRGBM
Cordgenics, LLC
Phase 3 Completed
NCT03149003 2023-11-15
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT00716976 2023-11-09
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
Children's Oncology Group
Phase 3 Completed
NCT02573324 2023-05-11
Intellance1
AbbVie
Phase 3 Completed
NCT02617589 2023-03-28
CheckMate 498
Bristol-Myers Squibb
Phase 3 Completed
NCT00377156 2022-09-16
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT01372774 2022-09-16
Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00369785 2021-10-20
Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
Wake Forest University Health Sciences
Phase 3 Completed
NCT00418691 2020-09-23
Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning
M.D. Anderson Cancer Center
Phase 3 Terminated
NCT01014767 2019-08-20
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
Tufts Medical Center
Phase 3 Terminated
NCT00820222 2019-04-02
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT00085098 2018-09-07
Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor
Children's Oncology Group
Phase 3 Completed
NCT00096265 2018-03-09
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00522951 2017-08-28
SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study
Bayer
Phase 3 Completed
NCT00566852 2017-08-21
Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00581113 2015-06-11
Neural Stem Cell Preserving Brain Radiation Therapy & Stereotactic Radiosurgery in Patients With 1-6 Brain Metastases
Virginia Commonwealth University
Phase 3 Terminated
NCT00761280 2014-11-14
SAPPHIRE
Isarna Therapeutics GmbH
Phase 3 Terminated
NCT00088166 2014-08-13
XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
Celtic Pharma Development Services
Phase 3 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00226655 2012-08-31
An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies
Celtic Pharma Development Services
Phase 3 Completed
NCT00154375 2011-04-26
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma
Novartis
Phase 3 Completed